Financhill
Sell
20

HEPA Quote, Financials, Valuation and Earnings

Last price:
$0.06
Seasonality move :
-23.16%
Day range:
$0.06 - $0.07
52-week range:
$0.04 - $56.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.34x
Volume:
49.2K
Avg. volume:
144.1K
1-year change:
-99.87%
Market cap:
$743.6K
Revenue:
--
EPS (TTM):
-$80.50

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
HEPA
Hepion Pharmaceuticals
-- -- -- -- --
BOLT
Bolt Biotherapeutics
$819.8K -$6.27 -35.71% -44.05% $2.00
CRMD
Cormedix
$35.2M $0.16 3606.46% -38.24% $19.00
KRYS
Krystal Biotech
$93.7M $1.26 35.76% 138.36% $205.20
PTIX
Protagenic Therapeutics
-- -- -- -- --
RIGL
Rigel Pharmaceuticals
$64.6M $1.41 75.29% 1057.82% $33.74
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
HEPA
Hepion Pharmaceuticals
$0.07 -- $743.6K -- $0.00 0% --
BOLT
Bolt Biotherapeutics
$5.91 $2.00 $11.3M -- $0.00 0% 1.14x
CRMD
Cormedix
$11.59 $19.00 $786.1M 52.68x $0.00 0% 8.67x
KRYS
Krystal Biotech
$141.35 $205.20 $4.1B 33.98x $0.00 0% 12.65x
PTIX
Protagenic Therapeutics
$3.48 -- $2M -- $0.00 0% 0.13x
RIGL
Rigel Pharmaceuticals
$18.62 $33.74 $332.8M 9.00x $0.00 0% 1.63x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
HEPA
Hepion Pharmaceuticals
-- 3.935 -- --
BOLT
Bolt Biotherapeutics
-- 0.622 -- 2.86x
CRMD
Cormedix
-- 3.276 -- 3.84x
KRYS
Krystal Biotech
-- 0.158 -- 9.06x
PTIX
Protagenic Therapeutics
-- 2.210 -- --
RIGL
Rigel Pharmaceuticals
76.29% 5.958 18.59% 1.78x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
HEPA
Hepion Pharmaceuticals
-- -$1.3M -- -- -- -$1.1M
BOLT
Bolt Biotherapeutics
-- -$12.1M -86.53% -86.53% -991.41% -$13.4M
CRMD
Cormedix
$37.5M $20.1M 23.7% 23.7% 52.85% $19.7M
KRYS
Krystal Biotech
$83.2M $36.2M 13.91% 13.91% 41.03% $24.8M
PTIX
Protagenic Therapeutics
-- -$1.4M -- -- -- -$1.1M
RIGL
Rigel Pharmaceuticals
$48.9M $12.8M 76.12% -- 25.06% -$893K

Hepion Pharmaceuticals vs. Competitors

  • Which has Higher Returns HEPA or BOLT?

    Bolt Biotherapeutics has a net margin of -- compared to Hepion Pharmaceuticals's net margin of -903.44%. Hepion Pharmaceuticals's return on equity of -- beat Bolt Biotherapeutics's return on equity of -86.53%.

    Company Gross Margin Earnings Per Share Invested Capital
    HEPA
    Hepion Pharmaceuticals
    -- -$2.15 --
    BOLT
    Bolt Biotherapeutics
    -- -$5.80 $46.8M
  • What do Analysts Say About HEPA or BOLT?

    Hepion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 2213922.14%. On the other hand Bolt Biotherapeutics has an analysts' consensus of $2.00 which suggests that it could grow by 576.82%. Given that Hepion Pharmaceuticals has higher upside potential than Bolt Biotherapeutics, analysts believe Hepion Pharmaceuticals is more attractive than Bolt Biotherapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    HEPA
    Hepion Pharmaceuticals
    0 0 0
    BOLT
    Bolt Biotherapeutics
    1 3 0
  • Is HEPA or BOLT More Risky?

    Hepion Pharmaceuticals has a beta of 1.688, which suggesting that the stock is 68.792% more volatile than S&P 500. In comparison Bolt Biotherapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock HEPA or BOLT?

    Hepion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bolt Biotherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals pays -- of its earnings as a dividend. Bolt Biotherapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HEPA or BOLT?

    Hepion Pharmaceuticals quarterly revenues are --, which are smaller than Bolt Biotherapeutics quarterly revenues of $1.2M. Hepion Pharmaceuticals's net income of -$6.1M is higher than Bolt Biotherapeutics's net income of -$11M. Notably, Hepion Pharmaceuticals's price-to-earnings ratio is -- while Bolt Biotherapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals is -- versus 1.14x for Bolt Biotherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HEPA
    Hepion Pharmaceuticals
    -- -- -- -$6.1M
    BOLT
    Bolt Biotherapeutics
    1.14x -- $1.2M -$11M
  • Which has Higher Returns HEPA or CRMD?

    Cormedix has a net margin of -- compared to Hepion Pharmaceuticals's net margin of 52.82%. Hepion Pharmaceuticals's return on equity of -- beat Cormedix's return on equity of 23.7%.

    Company Gross Margin Earnings Per Share Invested Capital
    HEPA
    Hepion Pharmaceuticals
    -- -$2.15 --
    CRMD
    Cormedix
    95.91% $0.30 $114.9M
  • What do Analysts Say About HEPA or CRMD?

    Hepion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 2213922.14%. On the other hand Cormedix has an analysts' consensus of $19.00 which suggests that it could grow by 63.93%. Given that Hepion Pharmaceuticals has higher upside potential than Cormedix, analysts believe Hepion Pharmaceuticals is more attractive than Cormedix.

    Company Buy Ratings Hold Ratings Sell Ratings
    HEPA
    Hepion Pharmaceuticals
    0 0 0
    CRMD
    Cormedix
    2 1 0
  • Is HEPA or CRMD More Risky?

    Hepion Pharmaceuticals has a beta of 1.688, which suggesting that the stock is 68.792% more volatile than S&P 500. In comparison Cormedix has a beta of 1.581, suggesting its more volatile than the S&P 500 by 58.146%.

  • Which is a Better Dividend Stock HEPA or CRMD?

    Hepion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cormedix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals pays -- of its earnings as a dividend. Cormedix pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HEPA or CRMD?

    Hepion Pharmaceuticals quarterly revenues are --, which are smaller than Cormedix quarterly revenues of $39.1M. Hepion Pharmaceuticals's net income of -$6.1M is lower than Cormedix's net income of $20.6M. Notably, Hepion Pharmaceuticals's price-to-earnings ratio is -- while Cormedix's PE ratio is 52.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals is -- versus 8.67x for Cormedix. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HEPA
    Hepion Pharmaceuticals
    -- -- -- -$6.1M
    CRMD
    Cormedix
    8.67x 52.68x $39.1M $20.6M
  • Which has Higher Returns HEPA or KRYS?

    Krystal Biotech has a net margin of -- compared to Hepion Pharmaceuticals's net margin of 40.52%. Hepion Pharmaceuticals's return on equity of -- beat Krystal Biotech's return on equity of 13.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    HEPA
    Hepion Pharmaceuticals
    -- -$2.15 --
    KRYS
    Krystal Biotech
    94.3% $1.20 $984.7M
  • What do Analysts Say About HEPA or KRYS?

    Hepion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 2213922.14%. On the other hand Krystal Biotech has an analysts' consensus of $205.20 which suggests that it could grow by 45.17%. Given that Hepion Pharmaceuticals has higher upside potential than Krystal Biotech, analysts believe Hepion Pharmaceuticals is more attractive than Krystal Biotech.

    Company Buy Ratings Hold Ratings Sell Ratings
    HEPA
    Hepion Pharmaceuticals
    0 0 0
    KRYS
    Krystal Biotech
    8 1 0
  • Is HEPA or KRYS More Risky?

    Hepion Pharmaceuticals has a beta of 1.688, which suggesting that the stock is 68.792% more volatile than S&P 500. In comparison Krystal Biotech has a beta of 0.675, suggesting its less volatile than the S&P 500 by 32.514%.

  • Which is a Better Dividend Stock HEPA or KRYS?

    Hepion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals pays -- of its earnings as a dividend. Krystal Biotech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HEPA or KRYS?

    Hepion Pharmaceuticals quarterly revenues are --, which are smaller than Krystal Biotech quarterly revenues of $88.2M. Hepion Pharmaceuticals's net income of -$6.1M is lower than Krystal Biotech's net income of $35.7M. Notably, Hepion Pharmaceuticals's price-to-earnings ratio is -- while Krystal Biotech's PE ratio is 33.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals is -- versus 12.65x for Krystal Biotech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HEPA
    Hepion Pharmaceuticals
    -- -- -- -$6.1M
    KRYS
    Krystal Biotech
    12.65x 33.98x $88.2M $35.7M
  • Which has Higher Returns HEPA or PTIX?

    Protagenic Therapeutics has a net margin of -- compared to Hepion Pharmaceuticals's net margin of --. Hepion Pharmaceuticals's return on equity of -- beat Protagenic Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    HEPA
    Hepion Pharmaceuticals
    -- -$2.15 --
    PTIX
    Protagenic Therapeutics
    -- -$2.75 --
  • What do Analysts Say About HEPA or PTIX?

    Hepion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 2213922.14%. On the other hand Protagenic Therapeutics has an analysts' consensus of -- which suggests that it could grow by 6336.78%. Given that Hepion Pharmaceuticals has higher upside potential than Protagenic Therapeutics, analysts believe Hepion Pharmaceuticals is more attractive than Protagenic Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    HEPA
    Hepion Pharmaceuticals
    0 0 0
    PTIX
    Protagenic Therapeutics
    0 0 0
  • Is HEPA or PTIX More Risky?

    Hepion Pharmaceuticals has a beta of 1.688, which suggesting that the stock is 68.792% more volatile than S&P 500. In comparison Protagenic Therapeutics has a beta of 0.354, suggesting its less volatile than the S&P 500 by 64.562%.

  • Which is a Better Dividend Stock HEPA or PTIX?

    Hepion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protagenic Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals pays -- of its earnings as a dividend. Protagenic Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HEPA or PTIX?

    Hepion Pharmaceuticals quarterly revenues are --, which are smaller than Protagenic Therapeutics quarterly revenues of --. Hepion Pharmaceuticals's net income of -$6.1M is lower than Protagenic Therapeutics's net income of -$1.4M. Notably, Hepion Pharmaceuticals's price-to-earnings ratio is -- while Protagenic Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals is -- versus 0.13x for Protagenic Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HEPA
    Hepion Pharmaceuticals
    -- -- -- -$6.1M
    PTIX
    Protagenic Therapeutics
    0.13x -- -- -$1.4M
  • Which has Higher Returns HEPA or RIGL?

    Rigel Pharmaceuticals has a net margin of -- compared to Hepion Pharmaceuticals's net margin of 21.46%. Hepion Pharmaceuticals's return on equity of -- beat Rigel Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    HEPA
    Hepion Pharmaceuticals
    -- -$2.15 --
    RIGL
    Rigel Pharmaceuticals
    91.73% $0.63 $78.3M
  • What do Analysts Say About HEPA or RIGL?

    Hepion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 2213922.14%. On the other hand Rigel Pharmaceuticals has an analysts' consensus of $33.74 which suggests that it could grow by 81.21%. Given that Hepion Pharmaceuticals has higher upside potential than Rigel Pharmaceuticals, analysts believe Hepion Pharmaceuticals is more attractive than Rigel Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    HEPA
    Hepion Pharmaceuticals
    0 0 0
    RIGL
    Rigel Pharmaceuticals
    1 4 0
  • Is HEPA or RIGL More Risky?

    Hepion Pharmaceuticals has a beta of 1.688, which suggesting that the stock is 68.792% more volatile than S&P 500. In comparison Rigel Pharmaceuticals has a beta of 1.264, suggesting its more volatile than the S&P 500 by 26.398%.

  • Which is a Better Dividend Stock HEPA or RIGL?

    Hepion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals pays -- of its earnings as a dividend. Rigel Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HEPA or RIGL?

    Hepion Pharmaceuticals quarterly revenues are --, which are smaller than Rigel Pharmaceuticals quarterly revenues of $53.3M. Hepion Pharmaceuticals's net income of -$6.1M is lower than Rigel Pharmaceuticals's net income of $11.4M. Notably, Hepion Pharmaceuticals's price-to-earnings ratio is -- while Rigel Pharmaceuticals's PE ratio is 9.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals is -- versus 1.63x for Rigel Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HEPA
    Hepion Pharmaceuticals
    -- -- -- -$6.1M
    RIGL
    Rigel Pharmaceuticals
    1.63x 9.00x $53.3M $11.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Robinhood Stock Keep Going Up?
Will Robinhood Stock Keep Going Up?

Commission-free online brokerage Robinhood (NASDAQ:HOOD) has served up massive gains…

Where Will Hershey Stock Be In 1 Year?
Where Will Hershey Stock Be In 1 Year?

Chocolate stocks used to be the epitome of sleepy stability,…

Where Will KNOT Stock Be In 1 Year?
Where Will KNOT Stock Be In 1 Year?

In the case of KNOT Offshore Partners (KNOP), most headlines…

Stock Ideas

Buy
63
Is NVDA Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 53x

Buy
60
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 42x

Sell
48
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
92
BGL alert for Jul 3

Blue Gold [BGL] is down 20.3% over the past day.

Sell
18
CNC alert for Jul 3

Centene [CNC] is down 1.3% over the past day.

Sell
12
MOH alert for Jul 3

Molina Healthcare [MOH] is up 0.3% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock